Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study
Journal: Multiple Sclerosis and Related Disorders; August 26, 2021
Author(s): Eoin P. Flanagan a, Michael Levy b, Eliezer Katz c, Daniel Cimbora c, Jorn Drappa c, Maureen A. Mealy c, Dewei She c, Bruce A.C. Cree
Effects of inebilizumab treatment in NMOSD patients who have previously been on rituximab
This study used data from the inebilizumab clinical trials (N-MOmentum trial) to assess whether the results achieved with this drug vary in any way for patients who have previously been on rituximab treatment. The results showed that inebilizumab had a comparable safety profile in participants with or without prior rituximab use and that patients with prior rituximab treatment did not have an increased risk of developing serious infections. Thus, inebilizumab may be a suitable treatment choice for individuals with neuromyelitis optica spectrum disorder who were previously treated with rituximab.
Free Access: Full text
